| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17:38 | New to The Street to Broadcast Executive Leadership Interviews Featuring Medicus Pharma Ltd., CitroTech, Vivos Therapeutics, Inc., and Virtuix Holdings on Bloomberg Television Tonight at 6:30 PM EST | 107 | ACCESS Newswire | The Show Will Also Air Across Latin America and MENA 1230 pm local time. NEW YORK CITY, NEW YORK / ACCESS Newswire / February 28, 2026 / New to The Street will broadcast nationally tonight at 6:30 PM... ► Artikel lesen | |
| 17:34 | Bayer ramps up hybrid seed output for Philippines, other markets | 3 | Philstar.com | ||
| 17:24 | Novo posts worst monthly decline as Lilly extends lead | 10 | Seeking Alpha | ||
| 16:26 | Harrow, Inc. (HROW): A Bull Case Theory | 1 | Insider Monkey | ||
| 12:54 | Benzinga Bulls And Bears: Rocket Lab, Kosmos Energy, Novo Nordisk - And Nvidia Fails To Boost Markets | 43 | Benzinga.com | ||
| 10:50 | NEWRON PHARMACEUTICALS SPA im strukturellen Fokus | 3 | Maximilian Berger | ||
| 09:54 | Cannabist Company Holdings Inc (The): Cannabist extends forbearance agreement until March 6 | 1 | Stockwatch | ||
| 08:07 | Novo's woes in spite of Ozempic's growth | 91 | RTE.ie | ||
| 05:29 | Prothena To Buy Back Up To $100 Mln Of Shares | 1 | RTTNews | ||
| 03:06 | Simply Solventless Concentrates Ltd: Simply Solventless begins restructuring process | 1 | Stockwatch | ||
| 02:18 | Josh Gottheimer makes key trades in Gilead Sciences and Intercontinental Exchange | 5 | Investing.com | ||
| 01:54 | Innocan Pharma Corp (2): Innocan receives FDA CVM sponsor fee waiver for LPT-CBD | 39 | Stockwatch | ||
| 01:30 | Vireo Growth Inc: SEC defendant Carey settles insider trading charges | 1 | Stockwatch | ||
| 01:30 | Verano Holdings Corp: SEC defendant Carey settles insider trading charges | 1 | Stockwatch | ||
| 01:30 | US IPO Weekly Recap: Asthma-focused Generate Biomedicines closes out February IPO market | 4 | Renaissance Capital | ||
| 00:31 | Here's Why I Won't Touch Teva Pharmaceutical With a 10-Foot Pole | 5 | The Motley Fool | ||
| Fr | Harrow Health Q4 2025 Earnings Preview | 3 | Seeking Alpha | ||
| Fr | JJK Holdings Ltd. Acquires $7,878,792 Convertible Debenture Of Noveris Health Sciences Inc.; Filing Of Early Warning Reports By JJK Holdings Ltd. And Pioneer Garage Limited | 2 | TheNewswire | ||
| Fr | Generate Biomedicines, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| Fr | Exact Sciences (EXAS) Merger with Abbott Moving Forward After Shareholder Approval | 2 | Insider Monkey |
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | Aktuelle Nachrichten | |||
|---|---|---|---|---|---|---|---|
| PROTHENA | 7 | 1 | 0,00 % | Prothena Corporation plc: Prothena Announces up to $100 Million Share Repurchase Plan | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced... ► Artikel lesen | ||
| BAYER | 6 | 36 | +0,39 % | Bayer Aktie: Alles vorbei? - Airbus, BB Biotech, BioNTech, TUI und Valneva - Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | ||
| NOVO NORDISK | 5 | 40 | -0,24 % | Novo Nordisk enttäuscht mit Abnehmspritze CagriSema - Eli Lillys Präparat überlegen | Der dänische Pharmakonzern Novo Nordisk hat mit seinem Kombipräparat CagriSema das primäre Ziel der Phase-3-Studie REDEFINE 4 verfehlt. Das Medikament erreichte nach 84 Wochen zwar einen Gewichtsverlust... ► Artikel lesen | ||
| GENERATE BIOMEDICINES | 4 | - | 0,00 % | Generate Biomedicines Prices IPO At $16/shr | WASHINGTON (dpa-AFX) - Generate Biomedicines, Inc. (GENB) on Thursday priced its initial public offering of 25,000,000 shares of stock at $16 per share, raising gross proceeds of $400 million.The... ► Artikel lesen | ||
| ELI LILLY | 3 | 125 | -0,11 % | Novo posts worst monthly decline as Lilly extends lead | |||
| NOVARTIS | 3 | 105 | +0,21 % | Novartis tritt in Indien den Rückzug an, um sich in Zukunft noch mehr auf das US-Geschäft konzentrieren zu können | Seit rund einem Jahr verstärkt Novartis seine Bemühungen um den US-Markt. Aus Furcht vor der trumpschen Zollkeule kündigte das Schweizer Unternehmen im vergangenen Frühjahr an, 23 Milliarden US-Dollar... ► Artikel lesen | ||
| HARROW | 3 | 4 | +0,44 % | Harrow Health Q4 2025 Earnings Preview | |||
| SIMPLY SOLVENTLESS CONCENTRATES | 3 | 3 | +0,65 % | XFRA Y3I: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSIMPLY SOLVENT.CONC.... ► Artikel lesen | ||
| MERCK & CO | 2 | 43 | -0,19 % | Pharma im Umbruch: Milliardenblockbuster vor Patentende: Merck baut Konzern radikal um | © Foto: JHVEPhoto - stock.adobe.com Merck stellt sein Pharmageschäft neu auf. Der Konzern reagiert auf das nahende Patentende seines Kassenschlagers Keytruda und setzt auf neue Wachstumstreiber.Der... ► Artikel lesen | ||
| ABBOTT LABORATORIES | 2 | 10 | -0,38 % | Exact Sciences (EXAS) Merger with Abbott Moving Forward After Shareholder Approval |
| Unternehmen / Aktien | Aktueller Kurs | Ø Kursziel (Euro) | Potential (Euro) | kaufen | halten | verkaufen | |||
|---|---|---|---|---|---|---|---|---|---|
| DOCMORRIS AG | 5,675 | 8,88 | +56 % | 4 | 5 | 3 | |||
| NOVO NORDISK A/S | 31,600 | 41,34 | +31 % | 22 | 22 | 4 | |||
| SCHOTT PHARMA AG & CO KGAA | 14,780 | 18,70 | +27 % | 8 | 16 | - | |||
| SANOFI SA | 81,41 | 97,62 | +20 % | 15 | 18 | - | |||
| MERCK KGAA | 128,60 | 140,50 | +9 % | 9 | 3 | - | |||
| ELI LILLY AND COMPANY | 889,90 | 968,78 | +9 % | 1 | - | - | |||
| BAYER AG | 42,010 | 43,36 | +3 % | 20 | 13 | 1 | |||
| PFIZER INC | 23,350 | 23,83 | +2 % | 1 | 6 | - | |||
| ROCHE HOLDING AG GS | 402,50 | 382,67 | -5 % | 12 | 22 | 5 | |||
| ASTRAZENECA PLC | 177,25 | 163,18 | -8 % | 20 | 1 | 5 | |||
| GSK PLC | 25,040 | 22,25 | -11 % | 4 | 13 | 12 | |||
| NOVARTIS AG | 142,44 | 126,17 | -11 % | 8 | 10 | 2 |